CANCER GENETICS AND GENOMICS LABORATORY PHARMACOGENOMICS REQUISITION

BC CANCER

DEPT. OF PATHOLOGY AND LABORATORY MEDICINE FAX: 604-877-6294 ROOM 3307 - 600 WEST 10TH AVENUE

604-877-6000 EXT 67-2094 Mon-Fri 8:30AM-4:30PM

CE	R v.	ANCOUVER BC V5	Z-4E6		WW.CANCERGENETICSLAB.CA ANCERGENETICSLAB@BCCANCER.BC.CA			
PATIENT INFORMATION						REQUESTING PHYSICIAN		
Last Name				First and Middle Names		Name	MSC	
Date of Birth (dd/mmm/yyyy) Gender Mal					Non Binary/Other/Not Disclosed	Phone	Fax	
PHN BC Car			BC Cano	incer ID Cerner MRN		Address	'	
Specimen						1		
Specimen T	pecimen Type Cerner Order:			DPYD Mutation So	creen	NOTE: PHYSICIAN SIGNATURE REQUIRED (BELOW)		
Periphe	Peripheral Blood Sunquest Order:		er:	DPYDMD		COPY PHYSICIANS (ALL INFORMATION IS NECESSARY)		
	Collection Instruction			Collect 1 x 6mL El		Name		MSC
			ructions:	delivery to Cancer Laboratory (see a	room temperature using overnight r Genetics and Genomics ddress above). Do not refrigerate	Address		
				or freeze.		Name	MSC	
Collection Date: (dd/mmm/yyyy)					Address			
REASON FOR TESTING						Name		MSC
DPYD Prospective testing (prior to first ever exposure to 5FU/Capecitabine)						Address		
Known/Suspected adverse reaction to 5FU/Capecitabine. DPYD genotype unknown								
Notes								
Testing is NOT indicated for patients who have previously demonstrated tolerance to fluoropyrimidine (5-fluorouracil (5-FU) or Capecitabine).								
PHYSICIAN SIGNATURE (REQUIRED)						DATE		
LAB USE	PB EDTA	Other						
ONLY								

CACG_CGL_3018 CGL PHARMACOGENOMICS REQUISITION

V.3.0 October 2025